If Smo expressed by CIN is in fact the relevant target of Smo antagonists and agonists that respectively promote or attenuate LID and Erk activation, then the conditional genetic loss or gain of function of Smo in CIN should phenocopy the pharmacological outcomes. Here, SMO is linked to cervical squamous intraepithelial neoplasia.